Talk:Strontium ranelate

From Wikipedia, the free encyclopedia

This is the talk page for discussing improvements to the Strontium ranelate article.
Please sign and date your posts by typing four tildes (~~~~). Put new text under old text. Click here to start a new topic. New to Wikipedia? Welcome! Ask questions, get answers. This is not a forum for general discussion about the article's subject.	Be polite Assume good faith No personal attacks Be welcoming	Article policies No original research Neutral point of view Verifiability

	Strontium ranelate is part of WikiProject Pharmacology, a project to improve all Pharmacology-related articles. If you would like to help improve this and other pharmacology articles, please join the project. All interested editors are welcome.
Start	This article has been rated as start-Class on the quality scale.
Mid	This article has been rated as mid-importance for this Project's importance scale.

How can I compare Protelos with other anti-osteoporotic drugs, like Fosamax and Actonel?

[edit] References

This article makes direct claims that should be supported by references. JFW | T@lk 07:42, 8 July 2007 (UTC)

[edit] Ranelic Acid

The foolowing material was removed from ranelic acid because it refers to strontium ranelate. But most of this material seems to already be here. RJFJR (talk) 02:24, 16 February 2008 (UTC)

An experimental drug made by combining strontium with ranelic acid has aided in bone growth, boosted bone density and lessened fractures. (El-Hajj, 2004) Women receiving the drug showed a 6.8% increase in bone density. Women receiving a placebo had a 1.3% decrease. (Meunier, et. al, 2004).

Oral Strontium ranelate (Protelosr, Protosr - Servier) is the first in a new class of drugs called a Dual Action Bone Agents (DABA's), and has proven efficacy in the prevention of vertebral and non-vertebral fractures (including hip fracture). Strontium Ranelate works by stimulating the proliferation of osteoblast (bone building) cells (there is some debate about this), and inhibiting the proliferation of osteoclast (bone absorbing) cells. This means that strontium Ranelate increases Bone mineral density (BMD) by forming new bone, rather than just preserving existing bone. In comparison to bisphosphonates which only act on one aspect of bone remodeling, strontium ranelate also preserves bone turnover, allowing the microarchitecture of the bone to be continuously repaired as it would in healthy bone. Strontium ranelate is taken as a 2g oral suspension daily, and is licenced for the treatment of osteoporosis to prevent vertebral and hip fracture (this may differ by country and is not approved in the USA). Strontium ranelate has show significant efficacy at reducing both vertebral, and non-vertebral fractures in patients over the age of 80, who are the most at risk where osteoporosis is concerned. Strontium ranelate has side effect benefits over the bisphosphonates, as it does not cause any form of upper GI side effect, which is the most common cause for medication withdrawal in osteoporosis.